Jing Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jing Liu has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
Haizhou Wang
Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
16 shared publicationsQiu Zhao
Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China
16 shared publicationsMeng Zhang
Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China
15 shared publications- Qiu Zhao
Zhongnan Hospital of Wuhan University
15 shared publications Zhenwei Yang
Department of Gastroenterology Zhongnan Hospital of Wuhan University Wuhan Hubei Province China
14 shared publicationsHailin Zhang
Department of Gastroenterology Zhongnan Hospital of Wuhan University Wuhan Hubei Province China
12 shared publications
Latest Publications
- 3 August 2026
- Published by Zhejiang University Press in Bio-Design and Manufacturing
- p. 1-14
High-throughput colorectal cancer organoid-on-a-chip for single-organoid-analysis-based personalized drug evaluation
Patient-derived colorectal cancer organoids (CRCOs) are increasingly recognized for their ability to preserve genetic, transcriptional, histological, and d
- 3 August 2026
- Published by Zhejiang University Press in Bio-Design and Manufacturing
- p. 1-14
High-throughput colorectal cancer organoid-on-a-chip for single-organoid-analysis-based personalized drug evaluation
Patient-derived colorectal cancer organoids (CRCOs) are increasingly recognized for their ability to preserve genetic, transcriptional, histological, and d
- Open Access
- 4 June 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Soft fibrin matrix instructs macrophage M2 polarization via FABP4-mediated enhancement of fatty acid β-oxidation to alleviate MASH
Background: Macrophage-driven inflammation is a key pathogenic factor in metabolic dysfunction-associated steatohepatitis (MASH). While fibrin deposition is observed in MASH livers, its role in regulating macrophage polarization and disease progression remains unclear. Methods: We investigated fibrin deposition in liver tissues from MASH patients and high-fat diet (HFD)-induced MASH mice. Macrophages were cultured in soft or stiff 3D fibrin matrices to assess polarization phenotypes. In vivo, macrophages pre-cultured in soft or stiff fibrin were adoptively transferred into HFD-fed mice. Mechanistic studies involved siRNA-mediated knockdown, overexpression, chromatin immunoprecipitation, co-immunoprecipitation, and metabolomic analyses. Macrophage-specific FABP4 knockdown was achieved using an AAV8 vector expressing F4/80-driven FABP4 shRNA and eGFP. Results: Fibrin deposition was significantly elevated in MASH livers and correlated with pro-inflammatory macrophage infiltration. Macrophages cultured in soft fibrin matrices exhibited enhanced anti-inflammatory (M2) polarization, characterized by increased Arg1 and CD206 and decreased iNOS and TNFα expression. Adoptive transfer of soft fibrin-cultured macrophages alleviated hepatic steatosis, insulin resistance, and oxidative stress in MASH mice. Mechanistically, soft fibrin downregulated FABP4 expression by inhibiting ITGB2/STAT1 signaling. FABP4 competitively bound to PPARα, thereby sterically hindering the access of USP53, which functions as a deubiquitinase, to PPARα. This displacement prevented USP53-mediated deubiquitination, resulting in increased PPARα ubiquitination and proteasomal degradation, ultimately leading to suppression of fatty acid β-oxidation. Macrophage-specific FABP4 knockdown mirrored the therapeutic effects of soft fibrin, ameliorating MASH pathology. Conclusions: Our findings reveal that soft fibrin matrices promote anti-inflammatory macrophage polarization and mitigate MASH by enhancing fatty acid β-oxidation via downregulation of FABP4 and stabilization of PPARα. Targeting the Fibrin-FABP4-PPARα axis may offer a novel therapeutic strategy for MASH.
- 4 June 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessSoft fibrin matrix instructs macrophage M2 polarization via FABP4-mediated enhancement of fatty acid β-oxidation to alleviate MASH
Background: Macrophage-driven inflammation is a key pathogenic factor in metabolic dysfunction-associated steatohepatitis (MASH). While fibrin deposition is observed in MASH livers, its role in regulating macrophage polarization and disease progression remains unclear. Methods: We investigated fibrin deposition in liver tissues from MASH patients and high-fat diet (HFD)-induced MASH mice. Macrophages were cultured in soft or stiff 3D fibrin matrices to assess polarization phenotypes. In vivo, macrophages pre-cultured in soft or stiff fibrin were adoptively transferred into HFD-fed mice. Mechanistic studies involved siRNA-mediated knockdown, overexpression, chromatin immunoprecipitation, co-immunoprecipitation, and metabolomic analyses. Macrophage-specific FABP4 knockdown was achieved using an AAV8 vector expressing F4/80-driven FABP4 shRNA and eGFP. Results: Fibrin deposition was significantly elevated in MASH livers and correlated with pro-inflammatory macrophage infiltration. Macrophages cultured in soft fibrin matrices exhibited enhanced anti-inflammatory (M2) polarization, characterized by increased Arg1 and CD206 and decreased iNOS and TNFα expression. Adoptive transfer of soft fibrin-cultured macrophages alleviated hepatic steatosis, insulin resistance, and oxidative stress in MASH mice. Mechanistically, soft fibrin downregulated FABP4 expression by inhibiting ITGB2/STAT1 signaling. FABP4 competitively bound to PPARα, thereby sterically hindering the access of USP53, which functions as a deubiquitinase, to PPARα. This displacement prevented USP53-mediated deubiquitination, resulting in increased PPARα ubiquitination and proteasomal degradation, ultimately leading to suppression of fatty acid β-oxidation. Macrophage-specific FABP4 knockdown mirrored the therapeutic effects of soft fibrin, ameliorating MASH pathology. Conclusions: Our findings reveal that soft fibrin matrices promote anti-inflammatory macrophage polarization and mitigate MASH by enhancing fatty acid β-oxidation via downregulation of FABP4 and stabilization of PPARα. Targeting the Fibrin-FABP4-PPARα axis may offer a novel therapeutic strategy for MASH.
- 21 May 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 26, 1-17
Leveraging a Disulfidptosis-related LncRNA Prognostic Signature to Indicate Immune Features and Drug Sensitivity of Gastric Cancer Based on Machine Learning
Introduction: Disulfidptosis is a newly identified, programmed cell death that could influence the progression, immune microenvironment, and therapeutic response of stomach adenocarcinoma (STAD). This mechanism is potentially regulated by long non-coding RNAs (lncRNAs). Materials and Methods: We analyzed TCGA datasets to identify 187 disulfidptosis-related lncRNAs (DRlncRNAs). Prognostic candidates were screened using univariate Cox, LASSO, and multivariate Cox analyses. Molecular subtypes were stratified via consensus clustering. Additionally, we construct a prognostic model based on key DRlncRNAs and evaluate its clinical relevance in terms of immune infiltration, functional pathways, drug responsiveness, and tumor mutation burden (TMB). Finally, expression validation of these DRlncRNAs was performed in STAD cell lines using qRT-PCR. Results: We established a three-DRlncRNA prognostic model demonstrating robust predictive performance with high AUC values. Patients in the low-risk subgroup exhibited favorable survival outcomes and greater sensitivity to immunotherapy. Conversely, the high-risk subgroup showed reduced survival, increased tumor malignancy, and poorer response to immunotherapy. qRT-PCR validation revealed significant expression differences of these three DRlncRNAs between gastric cancer cell lines and normal gastric epithelial cell lines. Discussion: DRlncRNAs were identified as potential biomarkers for prognostic and immune profiling in STAD. The identified signature may reflect biological activities associated with disulfidptosis and suggest potential therapeutic targets. Further mechanistic and translational studies are needed to determine whether these DRlncRNAs directly regulate disulfidptosis and to support clinical applications Conclusion: This DRlncRNA-based prognostic model demonstrates strong predictive power for survival outcomes in STAD, offering guidance for personalized treatment strategies.
- 21 May 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 26, 1-17
Leveraging a Disulfidptosis-related LncRNA Prognostic Signature to Indicate Immune Features and Drug Sensitivity of Gastric Cancer Based on Machine Learning
Introduction: Disulfidptosis is a newly identified, programmed cell death that could influence the progression, immune microenvironment, and therapeutic response of stomach adenocarcinoma (STAD). This mechanism is potentially regulated by long non-coding RNAs (lncRNAs). Materials and Methods: We analyzed TCGA datasets to identify 187 disulfidptosis-related lncRNAs (DRlncRNAs). Prognostic candidates were screened using univariate Cox, LASSO, and multivariate Cox analyses. Molecular subtypes were stratified via consensus clustering. Additionally, we construct a prognostic model based on key DRlncRNAs and evaluate its clinical relevance in terms of immune infiltration, functional pathways, drug responsiveness, and tumor mutation burden (TMB). Finally, expression validation of these DRlncRNAs was performed in STAD cell lines using qRT-PCR. Results: We established a three-DRlncRNA prognostic model demonstrating robust predictive performance with high AUC values. Patients in the low-risk subgroup exhibited favorable survival outcomes and greater sensitivity to immunotherapy. Conversely, the high-risk subgroup showed reduced survival, increased tumor malignancy, and poorer response to immunotherapy. qRT-PCR validation revealed significant expression differences of these three DRlncRNAs between gastric cancer cell lines and normal gastric epithelial cell lines. Discussion: DRlncRNAs were identified as potential biomarkers for prognostic and immune profiling in STAD. The identified signature may reflect biological activities associated with disulfidptosis and suggest potential therapeutic targets. Further mechanistic and translational studies are needed to determine whether these DRlncRNAs directly regulate disulfidptosis and to support clinical applications Conclusion: This DRlncRNA-based prognostic model demonstrates strong predictive power for survival outcomes in STAD, offering guidance for personalized treatment strategies.
- 11 June 2025
- Published by Springer Nature in Molecular and Cellular Biochemistry
- p. 1-18
TAP1 promotes immune escape by activating JNK/STAT1/PD-L1 signaling in EBV-associated gastric cancer
Epstein–Barr virus (EBV) infection accounts for approximately 10% of gastric cancer (GC) cases and is strongly linked to immune evasion, although the precise mechanisms remain unclear. Transporter associated with antigen processing 1 (TAP1), a member of ATP-binding cassette subfamily B, is overexpressed in EBV-associated gastric cancer (EBVaGC) and is implicated in tumor immune evasion. TAP1 expression levels in EBV-positive and EBV-negative gastric cancer samples were analyzed using TCGA and GEO datasets. Molecular biology techniques were used to investigate the regulatory pathways involved in TAP1. The role of TAP1 in modulating immunotherapy responses was validated using T-cell cytotoxicity assays and mouse models. TAP1 was significantly overexpressed in EBV-positive gastric cancer tissues and cell lines. Mechanistic studies revealed that EBV latent membrane protein 2A (LMP2A) activates the NF-κB P65 pathway, which directly binds to the TAP1 promoter and enhances transcription. Furthermore, TAP1 expression was positively correlated with PD-L1 levels. In immunocompetent mice, shTAP1 MFC cells exhibited significantly reduced growth relative to that in immunodeficient mice. TAP1 upregulates PD-L1 via the JNK/STAT1 pathway, thereby influencing tumor immunotherapy responses. Notably, TAP1 silencing combined with PD-1 monoclonal antibody treatment significantly inhibited gastric cancer cell proliferation. This study revealed a mechanism through which the EBV protein LMP2A drives TAP1 expression via NF-κB signaling. TAP1, in turn, regulates PD-L1 expression via the JNK/STAT1 pathway, contributing to immune evasion. These findings highlight TAP1 as a promising therapeutic target for improving the efficacy of immunotherapy in gastric cancer.
- 11 June 2025
- Published by Springer Nature in Molecular and Cellular Biochemistry
- p. 1-18
TAP1 promotes immune escape by activating JNK/STAT1/PD-L1 signaling in EBV-associated gastric cancer
Epstein–Barr virus (EBV) infection accounts for approximately 10% of gastric cancer (GC) cases and is strongly linked to immune evasion, although the precise mechanisms remain unclear. Transporter associated with antigen processing 1 (TAP1), a member of ATP-binding cassette subfamily B, is overexpressed in EBV-associated gastric cancer (EBVaGC) and is implicated in tumor immune evasion. TAP1 expression levels in EBV-positive and EBV-negative gastric cancer samples were analyzed using TCGA and GEO datasets. Molecular biology techniques were used to investigate the regulatory pathways involved in TAP1. The role of TAP1 in modulating immunotherapy responses was validated using T-cell cytotoxicity assays and mouse models. TAP1 was significantly overexpressed in EBV-positive gastric cancer tissues and cell lines. Mechanistic studies revealed that EBV latent membrane protein 2A (LMP2A) activates the NF-κB P65 pathway, which directly binds to the TAP1 promoter and enhances transcription. Furthermore, TAP1 expression was positively correlated with PD-L1 levels. In immunocompetent mice, shTAP1 MFC cells exhibited significantly reduced growth relative to that in immunodeficient mice. TAP1 upregulates PD-L1 via the JNK/STAT1 pathway, thereby influencing tumor immunotherapy responses. Notably, TAP1 silencing combined with PD-1 monoclonal antibody treatment significantly inhibited gastric cancer cell proliferation. This study revealed a mechanism through which the EBV protein LMP2A drives TAP1 expression via NF-κB signaling. TAP1, in turn, regulates PD-L1 expression via the JNK/STAT1 pathway, contributing to immune evasion. These findings highlight TAP1 as a promising therapeutic target for improving the efficacy of immunotherapy in gastric cancer.
- Open Access
- 14 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (S 01) , E560-E561
Confocal endoscopy-assisted diagnosis of duodenal follicular lymphoma: a rare case report
Duodenal follicular lymphoma (D-FL), a rare gastrointestinal lymphoma, poses diagnostic challenges due to nonspecific symptoms [1] [2]. This case highlights the utility of confocal laser endomicroscopy (CLE) in early detection and management. A 59-year-old woman with bronchial asthma presented with epigastric pain and bloating. Gastroscopy revealed mucosal thickening and erosions at the duodenal bulb-descending junction ([Fig. 1] a). CLE identified disrupted glandular architecture, dilated lymphatic vessels, and fluorescein leakage, prompting targeted biopsies ([Fig. 1] b, [Video 1]). Histopathology confirmed neoplastic follicles ([Fig. 2]), while immunohistochemistry (CD20+, CD10+, Bcl-6+, BCL2+, and Ki-67+) and IG gene rearrangement confirmed follicular lymphoma. PET/CT ([Fig. 3] a) and abdominal CT ([Fig. 3] b) localized disease to the duodenum without extraintestinal involvement (stage II). Treatment began with Rituximab-CVP (cyclophosphamide, vincristine, and prednisone) for four cycles, achieving remission. Due to asthma-related concerns, therapy was switched to Rituximab-Lenalidomide, which was well-tolerated. Regular follow-up was advised to monitor progression. CLE’s real-time, high-resolution imaging enabled early detection of microarchitectural abnormalities, guiding precise biopsies and minimizing invasive sampling. Multimodal imaging (PET/CT, CT) confirmed localized disease, underscoring its role in staging. This case illustrates the synergy of advanced endoscopy, histopathology, and imaging in diagnosing D-FL. Personalized treatment, balancing efficacy and comorbidities, optimized outcomes without compromising safety. In conclusion, CLE enhances early diagnosis of D-FL by visualizing microscopic changes, complementing traditional methods. Combined with tailored therapies and rigorous follow-up, it improves diagnostic accuracy and long-term management in rare gastrointestinal malignancies. Endoscopy_UCTN_Code_CCL_1AB_2AZ_3AB Article published online: 13 June 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 14 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (S 01) , E560-E561
Open AccessConfocal endoscopy-assisted diagnosis of duodenal follicular lymphoma: a rare case report
Duodenal follicular lymphoma (D-FL), a rare gastrointestinal lymphoma, poses diagnostic challenges due to nonspecific symptoms [1] [2]. This case highlights the utility of confocal laser endomicroscopy (CLE) in early detection and management. A 59-year-old woman with bronchial asthma presented with epigastric pain and bloating. Gastroscopy revealed mucosal thickening and erosions at the duodenal bulb-descending junction ([Fig. 1] a). CLE identified disrupted glandular architecture, dilated lymphatic vessels, and fluorescein leakage, prompting targeted biopsies ([Fig. 1] b, [Video 1]). Histopathology confirmed neoplastic follicles ([Fig. 2]), while immunohistochemistry (CD20+, CD10+, Bcl-6+, BCL2+, and Ki-67+) and IG gene rearrangement confirmed follicular lymphoma. PET/CT ([Fig. 3] a) and abdominal CT ([Fig. 3] b) localized disease to the duodenum without extraintestinal involvement (stage II). Treatment began with Rituximab-CVP (cyclophosphamide, vincristine, and prednisone) for four cycles, achieving remission. Due to asthma-related concerns, therapy was switched to Rituximab-Lenalidomide, which was well-tolerated. Regular follow-up was advised to monitor progression. CLE’s real-time, high-resolution imaging enabled early detection of microarchitectural abnormalities, guiding precise biopsies and minimizing invasive sampling. Multimodal imaging (PET/CT, CT) confirmed localized disease, underscoring its role in staging. This case illustrates the synergy of advanced endoscopy, histopathology, and imaging in diagnosing D-FL. Personalized treatment, balancing efficacy and comorbidities, optimized outcomes without compromising safety. In conclusion, CLE enhances early diagnosis of D-FL by visualizing microscopic changes, complementing traditional methods. Combined with tailored therapies and rigorous follow-up, it improves diagnostic accuracy and long-term management in rare gastrointestinal malignancies. Endoscopy_UCTN_Code_CCL_1AB_2AZ_3AB Article published online: 13 June 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
- 14 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (S 01) , E402-E404
Synchronous multiple primary early stage esophageal cancers diagnosed in a teenager using confocal laser endomicroscopy
Esophageal cancer predominantly affects the elderly and is often overlooked in the young, resulting in patients presenting at advanced disease stages with poorer survival [1]. Early diagnosis is pivotal. Confocal laser endomicroscopy (CLE) holds significant promise in diagnosing and monitoring early upper gastrointestinal tract cancers. In a previous study, we reported the use of CLE to image a gastric adenocarcinoma, fundic gland type [2], thereby aiding diagnosis. We now report the case of a 16-year-old boy with a 1-year history of intermittent epigastric pain who underwent an esophagogastroduodenoscopy (EGD) that revealed multiple esophageal lesions. The EGD identified two 0-IIb lesions at 23–25 cm and 30 cm from the incisors, featuring patchy, reddish mucosa with clear borders ([Fig. 1] a, b). Magnification endoscopy with narrow-band imaging (ME-NBI) showed brownish, regularly patterned lesions, classified as B1 according to the Japanese Society of Esophagus criteria ([Fig. 1] c, d). Lugol iodine chromoendoscopy revealed Lugol-voiding lesions, with a pink sign later transitioning to a bright silver sign under NBI ([Fig. 1] e–h). CLE demonstrated white feathery substances, detached cells, the absence of localized squamous epithelium, thickened intrapapillary capillary loops, and normal peristalsis ([Fig. 2]; [Video 1]). The patient underwent complete endoscopic submucosal dissection (ESD) of both lesions ([Fig. 3]) Histopathology showed the lesion at 23 cm from the incisors to be a 0.9 × 0.6-cm squamous cell carcinoma, invading the submucosa and affecting submucous glands/ducts (200 μm), with INFb pattern ([Fig. 4] a). The other lesion showed high grade dysplasia ([Fig. 4] b). Immunohistochemical testing showed Ki-67 positivity in the epithelial layer. A diagnosis of synchronous multiple primary early esophageal cancer (T1aN0M0) was made. Multiple esophageal cancers have a poorer prognosis, necessitating surgery, radiotherapy, or chemotherapy [3] [4]. In this case, the patient underwent radiotherapy post-ESD. For patients with esophageal cancer who do not have tobacco and alcohol as risk factors, endoscopists should thoroughly examine the esophageal region for synchronous lesions. The CLE biopsy technique is safe, repeatable, and noninvasive, and demonstrates high sensitivity and specificity for early superficial esophageal squamous cell carcinoma, addressing the limitations of high definition white-light endoscopy and low resolution NBI, and the diagnostic variability of flexible indigo carmine-enhanced chromoendoscopy [5]. Endoscopy_UCTN_Code_TTT_1AO_2AB Article published online: 14 May 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 14 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (S 01) , E402-E404
Open AccessSynchronous multiple primary early stage esophageal cancers diagnosed in a teenager using confocal laser endomicroscopy
Esophageal cancer predominantly affects the elderly and is often overlooked in the young, resulting in patients presenting at advanced disease stages with poorer survival [1]. Early diagnosis is pivotal. Confocal laser endomicroscopy (CLE) holds significant promise in diagnosing and monitoring early upper gastrointestinal tract cancers. In a previous study, we reported the use of CLE to image a gastric adenocarcinoma, fundic gland type [2], thereby aiding diagnosis. We now report the case of a 16-year-old boy with a 1-year history of intermittent epigastric pain who underwent an esophagogastroduodenoscopy (EGD) that revealed multiple esophageal lesions. The EGD identified two 0-IIb lesions at 23–25 cm and 30 cm from the incisors, featuring patchy, reddish mucosa with clear borders ([Fig. 1] a, b). Magnification endoscopy with narrow-band imaging (ME-NBI) showed brownish, regularly patterned lesions, classified as B1 according to the Japanese Society of Esophagus criteria ([Fig. 1] c, d). Lugol iodine chromoendoscopy revealed Lugol-voiding lesions, with a pink sign later transitioning to a bright silver sign under NBI ([Fig. 1] e–h). CLE demonstrated white feathery substances, detached cells, the absence of localized squamous epithelium, thickened intrapapillary capillary loops, and normal peristalsis ([Fig. 2]; [Video 1]). The patient underwent complete endoscopic submucosal dissection (ESD) of both lesions ([Fig. 3]) Histopathology showed the lesion at 23 cm from the incisors to be a 0.9 × 0.6-cm squamous cell carcinoma, invading the submucosa and affecting submucous glands/ducts (200 μm), with INFb pattern ([Fig. 4] a). The other lesion showed high grade dysplasia ([Fig. 4] b). Immunohistochemical testing showed Ki-67 positivity in the epithelial layer. A diagnosis of synchronous multiple primary early esophageal cancer (T1aN0M0) was made. Multiple esophageal cancers have a poorer prognosis, necessitating surgery, radiotherapy, or chemotherapy [3] [4]. In this case, the patient underwent radiotherapy post-ESD. For patients with esophageal cancer who do not have tobacco and alcohol as risk factors, endoscopists should thoroughly examine the esophageal region for synchronous lesions. The CLE biopsy technique is safe, repeatable, and noninvasive, and demonstrates high sensitivity and specificity for early superficial esophageal squamous cell carcinoma, addressing the limitations of high definition white-light endoscopy and low resolution NBI, and the diagnostic variability of flexible indigo carmine-enhanced chromoendoscopy [5]. Endoscopy_UCTN_Code_TTT_1AO_2AB Article published online: 14 May 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
- 17 October 2024
- Published by Wiley in Cancer Science
- Vol. 116 (1) , 29-43
SET facilitates immune escape of microsatellite stability colorectal cancer by inhibiting c‐Myc degradation
Microsatellite stability (MSS) colorectal cancer (CRC) exhibits a low mutation load and poor immunogenicity, contributing to immune escape of tumor cells and less benefit from immune checkpoint blockade (ICB) treatment. The mechanisms underlying immunotherapeutic resistance in MSS CRC remain to be elucidated. Here, we identified that nuclear proto‐oncogene SET is significantly higher expressed in MSS CRC compared to microsatellite instability (MSI) CRC and facilitates immune escape of MSS CRC. Mechanistically, SET represses the expression of C‐C motif chemokine ligand 5 (CCL5) and upregulates mismatch repair (MMR) proteins expression in a c‐Myc‐dependent manner, which inhibits infiltration and migration of CD8+ T cells to tumor tissues and results in low immunogenicity in MSS CRC. In addition, we found that SET impairs ubiquitination and proteasomal degradation of c‐Myc by disrupting the interaction between E3 ligase FBXW7 and c‐Myc. Moreover, SET inhibition enhances the response to immunotherapy in MSS CRC in vivo. Overall, this study reveals the critical roles and posttranslational regulatory mechanism of SET in immune escape and highlights the SET/c‐Myc axis as a potential target for immunotherapy of MSS CRC that have implications for targeting a unique aspect of this disease.
- 17 October 2024
- Published by Wiley in Cancer Science
- Vol. 116 (1) , 29-43
Open AccessSET facilitates immune escape of microsatellite stability colorectal cancer by inhibiting c‐Myc degradation
Microsatellite stability (MSS) colorectal cancer (CRC) exhibits a low mutation load and poor immunogenicity, contributing to immune escape of tumor cells and less benefit from immune checkpoint blockade (ICB) treatment. The mechanisms underlying immunotherapeutic resistance in MSS CRC remain to be elucidated. Here, we identified that nuclear proto‐oncogene SET is significantly higher expressed in MSS CRC compared to microsatellite instability (MSI) CRC and facilitates immune escape of MSS CRC. Mechanistically, SET represses the expression of C‐C motif chemokine ligand 5 (CCL5) and upregulates mismatch repair (MMR) proteins expression in a c‐Myc‐dependent manner, which inhibits infiltration and migration of CD8+ T cells to tumor tissues and results in low immunogenicity in MSS CRC. In addition, we found that SET impairs ubiquitination and proteasomal degradation of c‐Myc by disrupting the interaction between E3 ligase FBXW7 and c‐Myc. Moreover, SET inhibition enhances the response to immunotherapy in MSS CRC in vivo. Overall, this study reveals the critical roles and posttranslational regulatory mechanism of SET in immune escape and highlights the SET/c‐Myc axis as a potential target for immunotherapy of MSS CRC that have implications for targeting a unique aspect of this disease.
- 11 June 2024
- Published by Wiley in Molecular Carcinogenesis
- Vol. 63 (9) , 1750-1767
The mechanism of RGS5 regulating gastric cancer mismatch repair protein
The incidence and mortality rates of gastric cancer (GC) remain alarmingly high worldwide, imposing a substantial healthcare burden. In this study, we utilized data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. A 4-gene prognostic model was developed to predict patient prognosis, and its accuracy was validated across multiple datasets. Patients with a low-risk score exhibited improved prognosis, elevated tumor mutation burden, heightened sensitivity to both immunotherapy and conventional chemotherapy. Notably, our investigation revealed that the key gene RGS5 positively modulates the expression of mismatch repair proteins via c-Myc. Furthermore, co-immunoprecipitation (COIP) assays demonstrated the interaction between RGS5 and c-Myc. Additionally, we confirmed that RGS5 regulates c-Myc through the ubiquitin-proteasome pathway. Moreover, RGS5 was identified as a positive regulator of PD-L1 expression and exhibited a negative correlation with the majority of immune cells. These findings underscore the potential of RGS5 as a novel biomarker and therapeutic target in the context of GC.
- 11 June 2024
- Published by Wiley in Molecular Carcinogenesis
- Vol. 63 (9) , 1750-1767
The mechanism of RGS5 regulating gastric cancer mismatch repair protein
The incidence and mortality rates of gastric cancer (GC) remain alarmingly high worldwide, imposing a substantial healthcare burden. In this study, we utilized data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. A 4-gene prognostic model was developed to predict patient prognosis, and its accuracy was validated across multiple datasets. Patients with a low-risk score exhibited improved prognosis, elevated tumor mutation burden, heightened sensitivity to both immunotherapy and conventional chemotherapy. Notably, our investigation revealed that the key gene RGS5 positively modulates the expression of mismatch repair proteins via c-Myc. Furthermore, co-immunoprecipitation (COIP) assays demonstrated the interaction between RGS5 and c-Myc. Additionally, we confirmed that RGS5 regulates c-Myc through the ubiquitin-proteasome pathway. Moreover, RGS5 was identified as a positive regulator of PD-L1 expression and exhibited a negative correlation with the majority of immune cells. These findings underscore the potential of RGS5 as a novel biomarker and therapeutic target in the context of GC.
- 20 October 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 172, 395-406
pH/ROS dual stimuli-responsive anionic flexible supramolecular organic frameworks for synergistic therapy
- 20 October 2023
- Published by Elsevier in Acta Biomaterialia
- Vol. 172, 395-406
pH/ROS dual stimuli-responsive anionic flexible supramolecular organic frameworks for synergistic therapy
- Open Access
- 27 September 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (9) , e007313
RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
Colon cancer is one of the most prevalent cancers and exhibits high mortality worldwide. Despite the certain success in the immunotherapy of many tumor types, the limited response of colon cancer to immunotherapy remains a difficult problem. Retinoic acid-inducible gene-I (RIG-I) is a crucial component in innate antiviral immunity, but its role in antitumor immunity remains unclear. Here, in this report, we found that silencing RIG-I decreased resistance to tumor cells killed by T cells and attenuated colon tumor growth in immunocompetent mice. Meanwhile, overexpressing RIG-I promoted tumor progression, and high expression of RIG-I sensitized cells to anti-programmed cell death protein-1 (PD-1) therapy in vivo. Interestingly, we found that RIG-I influenced programmed cell death ligand 1 (PD-L1) expression to promote colon cancer immune evasion without relying on type I interferon stimulation. Mechanistically, RIG-I could compete with Speckle Type POZ protein (SPOP) to bind PD-L1, leading to attenuation of the polyubiquitination and proteasomal degradation of PD-L1. Collectively, our work reveals new insights into the contribution of RIG-I to driving immune evasion by maintaining the stability of PD-L1 through post-translational modification and provides a promising biomarker of the efficacy of immunotherapy in colon cancer.
- 27 September 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (9) , e007313
Open AccessRIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
Colon cancer is one of the most prevalent cancers and exhibits high mortality worldwide. Despite the certain success in the immunotherapy of many tumor types, the limited response of colon cancer to immunotherapy remains a difficult problem. Retinoic acid-inducible gene-I (RIG-I) is a crucial component in innate antiviral immunity, but its role in antitumor immunity remains unclear. Here, in this report, we found that silencing RIG-I decreased resistance to tumor cells killed by T cells and attenuated colon tumor growth in immunocompetent mice. Meanwhile, overexpressing RIG-I promoted tumor progression, and high expression of RIG-I sensitized cells to anti-programmed cell death protein-1 (PD-1) therapy in vivo. Interestingly, we found that RIG-I influenced programmed cell death ligand 1 (PD-L1) expression to promote colon cancer immune evasion without relying on type I interferon stimulation. Mechanistically, RIG-I could compete with Speckle Type POZ protein (SPOP) to bind PD-L1, leading to attenuation of the polyubiquitination and proteasomal degradation of PD-L1. Collectively, our work reveals new insights into the contribution of RIG-I to driving immune evasion by maintaining the stability of PD-L1 through post-translational modification and provides a promising biomarker of the efficacy of immunotherapy in colon cancer.